ADMA Biologics (ADMA) to Release Quarterly Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) will likely be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $112.77 million for the quarter.

ADMA Biologics Trading Up 1.7 %

NASDAQ ADMA opened at $16.17 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm’s fifty day moving average price is $17.21 and its 200 day moving average price is $17.87. The company has a market capitalization of $3.82 billion, a price-to-earnings ratio of 57.75 and a beta of 0.75. ADMA Biologics has a 12 month low of $5.02 and a 12 month high of $23.64.

Insiders Place Their Bets

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ADMA shares. HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.